Log In Sign up
The largest database of trusted experimental protocols

Her2 cish pharmdx kit

Manufactured by Agilent Technologies
Visit Supplier

The HER2 CISH pharmDx kit is a laboratory equipment product designed for the detection of the HER2 gene in formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue samples. The kit utilizes chromogenic in situ hybridization (CISH) technology to visualize the HER2 gene status within the cells.

Automatically generated - may contain errors

Lab products found in correlation

Histology fish accessory kit, by Agilent Technologies (1 mentions) Dako cytomation autostainer plus, by Agilent Technologies (1 mentions)

3 protocols using her2 cish pharmdx kit

1

Characterization of Breast Cancer Liver Metastasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cases of breast cancer liver metastasis were characterized for intrinsic molecular subtype as per published guidelines55 (link). In brief, FFPE sections were stained for ER, PgR, HER2 or Ki67 and scored by a pathologist. For both ER and PgR, positive staining in ≥1% of tumor cell nuclei was required in order for the case to be considered receptor positive56 (link). For HER2, the following system was utilized: 0 or 1+ (HER2 negative), 2+ (HER2 borderline), or 3+ (HER2 positive)57 (link). HER2 borderline cases underwent additional testing using HER2 CISH pharmDx kit (SK109, Dako) to test for HER2 amplification. The presence of HER2 amplification was considered to indicate that the case was HER2 positive. Cases were deemed Ki67 ‘low’ if <14% of nuclei were Ki67 positive, otherwise they were considered to be Ki67 ‘high.’ The results of the ER, PgR, HER2 and Ki67 analysis were then used to assign each case to an intrinsic molecular subtype according to the criteria recommended by Goldhirsch et al55 (link) as detailed in Supplementary Table 13.
Frentzas S., Simoneau E., Bridgeman V.L., Vermeulen P.B., Foo S., Kostaras E., Nathan M., Wotherspoon A., Gao Z.H., Shi Y., Van den Eynden G., Daley F., Peckitt C., Tan X., Salman A., Lazaris A., Gazinska P., Berg T.J., Eltahir Z., Ritsma L., Van Rheenen J., Khashper A., Brown G., Nystrom H., Sund M., Van Laere S., Loyer E., Dirix L., Cunningham D., Metrakos P, & Reynolds A.R. (2016). Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nature medicine, 22(11), 1294-1302.
+ Open protocol
+ Expand
2

Characterization of Breast Cancer Liver Metastasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cases of breast cancer liver metastasis were characterized for intrinsic molecular subtype as per published guidelines55 (link). In brief, FFPE sections were stained for ER, PgR, HER2 or Ki67 and scored by a pathologist. For both ER and PgR, positive staining in ≥1% of tumor cell nuclei was required in order for the case to be considered receptor positive56 (link). For HER2, the following system was utilized: 0 or 1+ (HER2 negative), 2+ (HER2 borderline), or 3+ (HER2 positive)57 (link). HER2 borderline cases underwent additional testing using HER2 CISH pharmDx kit (SK109, Dako) to test for HER2 amplification. The presence of HER2 amplification was considered to indicate that the case was HER2 positive. Cases were deemed Ki67 ‘low’ if <14% of nuclei were Ki67 positive, otherwise they were considered to be Ki67 ‘high.’ The results of the ER, PgR, HER2 and Ki67 analysis were then used to assign each case to an intrinsic molecular subtype according to the criteria recommended by Goldhirsch et al55 (link) as detailed in Supplementary Table 13.
Frentzas S., Simoneau E., Bridgeman V.L., Vermeulen P.B., Foo S., Kostaras E., Nathan M., Wotherspoon A., Gao Z.H., Shi Y., Van den Eynden G., Daley F., Peckitt C., Tan X., Salman A., Lazaris A., Gazinska P., Berg T.J., Eltahir Z., Ritsma L., Van Rheenen J., Khashper A., Brown G., Nystrom H., Sund M., Van Laere S., Loyer E., Dirix L., Cunningham D., Metrakos P, & Reynolds A.R. (2016). Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nature medicine, 22(11), 1294-1302.
+ Open protocol
+ Expand
3

Fluorescence In Situ Hybridization for Breast Cancer Markers

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
For the present study, fluorescence in situ hybridisation (FISH) was employed for detection of TOP2A and chromosome 17 according to the manufacturer`s guidelines. Pretreatment was done using Histology FISH Accessory Kit, code K5799 (Dako). The probe mix (VYSIS TOP2A/CEP 17 FISH Probe Kit, code 03N89-020 Abbott Molecular Inc) was applied and denatured at 73°C for 5 min before hybridisation at 37°C overnight. For HER2 and chromosome 17, the HER2 CISH pharmDx Kit, code 109 (Dako), was used and immunostaining for ER (ER SP1 Cell Marqque 33 mg/mL 1:100) and PR (PR 16 Novocastra 360 mg/mL 1:400) was done in a DakoCytomation Autostainer Plus (Dako) using Dako REAL EnVision Detection System with Peroxidase/DAB+, Rabbit/Mouse, code K5007, as previously described.5 (link)
Engstrøm M.J., Ytterhus B., Vatten L.J., Opdahl S, & Bofin A.M. (2014). TOP2A gene copy number change in breast cancer. Journal of Clinical Pathology, 67(5), 420-425.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!